• Bradford Protein Assay Kit: Practical Workflow

  2026-08-19

  The Bradford Protein Assay Kit K4103 provides a rapid biochemical protein assay for estimating protein concentration from small sample volumes using Coomassie Brilliant Blue G-250 and absorbance at 595 nm. It is best suited to clear, compatible solutions for enzyme, purification, and molecular biology workflows; samples containing substantial detergent, salt, color, or turbidity require validation or an alternative method.

• IDH1-R132H Autopalmitoylation in Cancer Cells

  2026-08-19

  A recent Nature Chemical Biology study identifies C269 autopalmitoylation as a mutation-associated regulatory mechanism that enhances IDH1-R132H activity and connects fatty-acid metabolism with oncogenic 2-HG production. Chemical proteomics, mutational analysis, biochemical assays, and cellular phenotyping together suggest that this modification is a mechanistically important and potentially druggable vulnerability in IDH1-mutant cancers.

• Nuclear mTORC1 and the TerminaTOR Strategy

  2026-08-18

  The reference study introduces TerminaTOR, a genetically encoded inhibitor that selectively perturbs mTORC1 at defined subcellular locations. By separating lysosomal from nuclear signaling, the authors show that nuclear mTORC1 regulates transcription of CCAAT motif-containing genes, revealing functional spatial organization beyond canonical nutrient sensing.

• CA800-PR Targets PR in HR+ Breast Cancer

  2026-08-18

  The reference study presents CA800-PR, a tumor-targeted heptamethine cyanine dye that combines near-infrared imaging with treatment of hormone receptor-positive breast cancer. In MCF-7 cells and xenograft tumors, the dye was associated with Golgi fragmentation, selective suppression of progesterone receptor expression, apoptosis, and recruitment of antitumor M1-type macrophages.

• RNA Pol II Loss Reveals an Active Death Signal

  2026-08-17

  Harper et al. show that RNA polymerase II inhibition can trigger apoptosis through active sensing of RNA Pol IIA loss rather than through passive depletion of transcripts and proteins. The study defines the Pol II degradation-dependent apoptotic response and uses genetic and chemogenetic profiling to connect nuclear Pol II status with mitochondrial death signaling, providing a framework for interpreting the lethality of transcription-targeting therapies.

• Perospirone: Integrated Neurovascular Research Workflows

  2026-08-17

  Perospirone (SM-9018 free base) supports mechanism-focused schizophrenia research while offering a practical entry point for investigating vascular Kv1.5 channel effects. This guide connects receptor pharmacology, patch-clamp electrophysiology, assay design, and troubleshooting around one experimentally versatile compound.

• Reactive Oxygen Species Assay Kit Workflow

  2026-08-16

  Build a controlled live-cell oxidative stress workflow with DCFH-DA fluorescence, Rosup validation, and normalization strategies. Translate ROS changes from PM2.5 and sulforaphane models into practical assay decisions for signaling, apoptosis, and therapeutic-response studies.

• HyperScript™ Reverse Transcriptase for Structured RNA

  2026-08-15

  Learn how to use HyperScript™ Reverse Transcriptase for reliable RNA to cDNA conversion when templates are structured, scarce, or unusually long. This workflow connects enzyme selection with RT-qPCR validation of transcriptional adaptations identified in IP3 receptor triple-knockout cell models.

• Pifithrin-α: A Practical p53 Inhibitor Workflow

  2026-08-14

  Pifithrin-α (PFTα) is a chemical p53 inhibitor for separating p53-driven stress responses from ferroptotic damage, apoptosis, and irradiation effects. This workflow translates a recent hippocampal neurotoxicity study into practical assay design, controls, optimization steps, and troubleshooting guidance.

• GPNMB Model Predicts ESCC Immunotherapy Response

  2026-08-14

  This study identifies circulating soluble GPNMB as a mechanistically active marker of immune checkpoint inhibitor resistance in esophageal squamous cell carcinoma. By integrating plasma GPNMB, CAF-Epi niche features, and clinicopathological variables, the authors develop a multimodal framework with potential value for response prediction and treatment stratification.

• Pexidartinib: Reading the TAM State

  2026-08-13

  Pexidartinib (PLX3397) is a selective CSF1R-directed tool for dissecting macrophage abundance, survival, and phenotype in cancer research. This article provides an assay-centered framework that connects CSF1R-mediated signaling inhibition with SPP1-focused tumor microenvironment macrophage modulation.

• Sulforaphane Workflows for Oxidative Stress Research

  2026-08-13

  Build reproducible Sulforaphane workflows that connect Keap1-Nrf2 signaling, reactive oxygen species, NLRP3 inflammasome activity, and cancer-related phenotypes. The approach combines cell-based dose finding with a literature-aligned DSS colitis model, giving researchers practical options for inflammation, oxidative stress, and chemoprevention studies.

• Cimetidine in BBB and Cancer Research Workflows

  2026-08-12

  Cimetidine can serve as a mechanistically distinctive histamine-2 receptor antagonist for H2R assays, gastrointestinal cancer research, and exploratory barrier-transport studies. This workflow combines controlled preparation, MOCK/MDR1 Transwell comparisons, recovery analysis, and practical troubleshooting to distinguish receptor biology from permeability artifacts.

• Network Medicine Identifies Apigenin for Alzheimer’s

  2026-08-12

  A 2025 study used network proximity analysis to screen flavonoids against Alzheimer’s disease targets and identified Apigenin as the leading candidate among four experimentally tested compounds. Cellular validation linked its neuroprotective activity to mitochondrial preservation, reduced apoptosis, AKT/NF-κB pathway suppression, and regulation of microglial inflammatory states.

• GPC3-HSP70 mRNA Nanovaccine in HCC

  2026-08-11

  The reference study develops an mRNA nanovaccine that combines tandem GPC3 CTL epitopes with HSP70 and tumor-targeting peptide assembly to stimulate antitumor T-cell immunity in hepatocellular carcinoma. Its combination with anti-PD-L1 therapy produced stronger immune and antitumor effects than either strategy alone, while also illustrating the design and quality-control considerations relevant to therapeutic mRNA production.

16801 records 1/1121 page Next 12345 下5页 Last page